Previous Close | 83.80 |
Open | 84.80 |
Bid | 82.42 x 300 |
Ask | 82.51 x 300 |
Day's Range | 82.32 - 84.80 |
52 Week Range | 76.02 - 99.56 |
Volume | |
Avg. Volume | 1,578,145 |
Market Cap | 15.654B |
Beta (5Y Monthly) | 0.32 |
PE Ratio (TTM) | 77.77 |
EPS (TTM) | 1.06 |
Earnings Date | Jul 29, 2024 - Aug 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 110.10 |
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in children with achondroplasia, as well as positive data for investigational uses in growth-related conditions, including idiopathic short stature (ISS) and Noonan syndrome, were presented at the 2024 Pediatric Endocrine Society (PES) Annual Meeting in Chicago, May 2-5, 2024. Researchers also presented results from additional studies highlighting the medicine'
Last week, you might have seen that BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) released its first-quarter result to...
Insightful Analysis of Biomarin Pharmaceutical Inc's Strengths, Weaknesses, Opportunities, and Threats